Professional Documents
Culture Documents
Current Management of Pulmonary Arterial Hypertension
Current Management of Pulmonary Arterial Hypertension
pulmonary arterial
hypertension
NURAMALINA BINTI REMAN
112016183
DR. RETNA DEWAYANI, SP. JP
Definition
Epoprostenol
• Short acting sodium salt, intravenous
• Improve haemodynamic, six-minute walk, survival
• Side effect : route of administration (infection,
thrombosis,embolism,leakage and pneumothorax)
Iloprost
• Longer half life (120 minute)
• Nebulizer (pulmonary selectivity and avoid systemic hypotension)
• Adjunctive therapy
Treatment
3. Endothelin-receptor antagonist
Bosentan
• Orally active dual receptor blocker (ET4 and ET8)
• Initiation of treatment at an early stage
• Hepatic dysfunction and teratogenic
Ambrisentan
Macitentan
4. Phophodiesterase inhibitor
Sildenafil : specific phosphodiesterase type-5
Side effect : flushing, epistaxis, heartburn, headache, interaction with
other drugs (bosentan and nitrates)
6. Prostacyclin-receptor agonist
Selexipag : target the same receptor as PGI2, but structurally
different
Side effect : headache, jaw pain, GI upset
Conclusion